prtk-s8.htm

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

This Registration Statement on Form S-8 is being filed to register an additional 2,585,590 shares under the Registrant’s 2015 Equity Incentive Plan and an additional 750,000 shares under the Registrant’s 2017 Inducement Plan, as amended. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-205482) filed with the Securities and Exchange Commission (the “SEC”) on July 2, 2015, its Registration Statement on Form S-8 (File No. 333-210053) filed with the SEC on March 9, 2016, its Registration Statement on Form S-8 (File No. 333-217660) filed with the SEC on May 4, 2017, its Registration Statement on Form S-8 (File No. 333-218847) filed with the SEC on June 20, 2017, its Registration Statement on Form S-8 (File No. 333-224781) filed with the SEC on May 9, 2018, its Registration Statement on Form S-8 (File No. 333-228218), filed with the SEC on November 6, 2018, its Registration Statement on Form S-8 (File No. 333-230097) filed with the SEC on March 6, 2019, its Registration Statement on Form S-8 (File No. 333-237084) filed with the SEC on March 11, 2020, and its Registration Statement on Form S-8 (File No. 333-254857), filed with the SEC on March 30, 2021.


			Incorporated by Reference
Exhibit Number		Description	Schedule / Form	File Number	Exhibit	Filing Date
	4.1	Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.	Form 8-K	001-36066	3.1	October 31, 2014

	4.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.	Form 8-K	001-36066	3.2	October 31, 2014

	4.3	Certificate of Elimination of Series A Junior Participating Preferred Stock.	Form 8-K	001-36066	3.1	July 24, 2015

	4.4	Amended and Restated Bylaws.	Form 8-K	001-36066	3.1	April 16, 2015

	4.5	Specimen Common Stock Certificate.	Form S-3	333-201458	4.2	January 12, 2015

	4.6	2015 Equity Incentive Plan.	Form S-8	333-205482	99.5	July 2, 2015

	4.7	Form of Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.	Form S-8	333-205482	99.6	July 2, 2015

	4.8	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.	Form S-8	333-205482	99.7	July 2, 2015

	4.9	Form of Leadership Team Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.	Form 8-K	001-36066	10.1	August 4, 2017

	4.10	Form of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.	Form 10-K	001-36066	10.6E	March 6, 2018

	4.11	Form of Director Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.	Form 10-K	001-36066	10.6F	March 6, 2018

	4.12	Paratek Pharmaceuticals 2017 Inducement Plan, as amended	Form 10-K	001-36066	10.6A	March 14, 2022

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 15th day of March, 2022.

Each person whose signature appears below constitutes and appoints Sarah Higgins and William M. Haskel, and each of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Paratek Pharmaceuticals, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

Signature	Title	Date

/s/ Evan Loh	Chief Executive Officer and Director	March 15, 2022
Evan Loh, M.D.	(Principal Executive Officer)

/s/ Sarah Higgins	Vice President, Finance and Controller	March 15, 2022
Sarah Higgins	(Principal Financial and Accounting Officer)

/s/ Michael F. Bigham	Executive Chairman and Director	March 15, 2022
Michael F. Bigham

/s/ Minnie Baylor-Henry	Director	March 15, 2022
Minnie Baylor-Henry

/s/ Thomas J. Dietz	Director	March 15, 2022
Thomas J. Dietz, Ph. D.

/s/ Timothy R. Franson	Director	March 15, 2022
Timothy R. Franson, M.D.

/s/ Rolf K. Hoffmann	Director	March 15, 2022
Rolf K. Hoffmann

/s/ Kristine Peterson	Director	March 15, 2022
Kristine Peterson


Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐


	PARATEK PHARMACEUTICALS, INC.

	By:	/s/ Evan Loh
		Name: Evan Loh, M.D.
		Title: Chief Executive Officer




William M. Haskel Chief Legal Officer, General Counsel and Corporate Secretary Paratek Pharmaceuticals, Inc. 75 Park Plaza Boston, MA 02116 (617) 807-6600		Thomas J. Danielski Christopher D. Comeau Ropes & Gray LLP Prudential Tower 800 Boylston Street Boston, MA 02199 (617) 951-7000

/s/ Robert S. Radie	Director	March 15, 2022
Robert S. Radie

/s/ Jeffrey Stein	Director	March 15, 2022
Jeffrey Stein, Ph.D.


	*	Filed herewith.